# SCTX (Scribe Therapeutics Inc.) - SEC EDGAR Financial Statements

> Scribe Therapeutics Inc. reported $187.9M in total assets through September 30, 2026 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/SCTX
- Markdown: https://convexityos.com/fundamentals/SCTX.md
- SEC CIK: 0001853921
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:41 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001853921&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2026 | -- | Sep 30, 2026 |
| Operating Income | FY 2026 | -- | Operating profit |
| Net Income | FY 2026 | -- | GAAP bottom line |
| Diluted EPS | FY 2026 | -- | Split-adjusted |
| Free Cash Flow | FY 2026 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $174.2M | Total debt: $5.14M |

## Income Statement

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $1.64M | $1.92M | -- | $20.11M | $4.90M | -- |
| Research & Development | $8.26M | $8.82M | -- | $14.42M | $13.88M | -- |
| Total Operating Expenses | $12.50M | $11.31M | -- | $17.95M | $16.52M | -- |
| **Operating Income** | -$10.86M | -$9.39M | -- | $2.16M | -$11.63M | -- |
| **EBITDA** | -$10.26M | -$8.79M | -- | $2.86M | -$10.93M | -- |
| Interest Expense | $0 | $276K | -- | $598K | $598K | -- |
| Income Before Tax | -$9.63M | -$6.26M | -- | $1.80M | -$10.62M | -- |
| Income Tax Expense | $231K | $212K | -- | $324K | -$712K | -- |
| **Net Income** | -$9.86M | -$6.48M | -$17.35M | $1.47M | -$9.90M | -$3.42M |
| Basic EPS | -$0.68 | -$2.62 | -- | $0.00 | -$4.08 | -- |
| **Diluted EPS** | -$0.68 | -$2.62 | -- | $0.00 | -$4.08 | -- |
| Basic Shares Outstanding | 14.5M | 2.5M | -- | 2.4M | 2.4M | -- |
| Diluted Shares Outstanding | 14.5M | 2.5M | -- | 2.4M | 2.4M | -- |

## Balance Sheet

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Dec 2025 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | $172.1M | $35.59M | $12.80M |
| Short-Term Investments | $2.18M | $7.42M | $45.17M |
| **Cash & Short-Term Investments** | $174.2M | $43.00M | $58.00M |
| **Total Current Assets** | $178.9M | $45.10M | $66.93M |
| Property, Plant & Equipment, Net | $5.15M | $5.75M | $7.01M |
| Other Non-Current Assets | $586K | $3.61M | $538K |
| **Total Non-Current Assets** | $9.04M | $12.82M | $11.29M |
| **Total Assets** | $187.9M | $57.93M | $78.22M |
| Accounts Payable | $2.77M | $2.77M | $4.57M |
| Deferred Revenue (Current) | $25.42M | $27.48M | $21.09M |
| **Total Current Liabilities** | $37.93M | $78.70M | $69.06M |
| Deferred Revenue (Non-Current) | $12.95M | $11.70M | $19.94M |
| Other Non-Current Liabilities | $8.15M | $7.92M | $7.49M |
| **Total Non-Current Liabilities** | $24.83M | $23.72M | $32.23M |
| **Total Liabilities** | $62.76M | $102.4M | $101.3M |
| **Total Debt (incl. Leases)** | $5.14M | $5.47M | $6.09M |
| Common Stock | $36K | $14K | $14K |
| Retained Earnings | -$191.4M | -$181.5M | -$157.7M |
| Accumulated Other Comp. Income | $0 | -$2.0K | $35K |
| **Total Stockholders' Equity** | $125.2M | -$164.8M | -$143.4M |
| Total Equity | $125.2M | -$164.8M | -$143.4M |

## Cash Flow Statement

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$9.86M | -$6.48M | -$17.35M | $1.47M | -$9.90M | -$3.42M |
| Depreciation & Amortization | $600K | $600K | -- | $700K | $700K | -- |
| Stock-Based Compensation | $1.22M | $227K | -- | $2.23M | $676K | -- |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Current Ratio | 4.72x | 0.57x | -- | -- | -- | -- |
| Quick Ratio | 4.59x | 0.55x | -- | -- | -- | -- |
| Debt to Equity | 0.04x | -- | -- | -- | -- | -- |
| **Revenue Growth (YoY)** | -91.9% | -60.8% | -- | -- | -- | -- |
| Operating Income Growth (YoY) | -602.6% | -- | -- | -- | -- | -- |
| **Net Income Growth (YoY)** | -770.0% | -- | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
